Johanna Baxter
Labour - Paisley and Renfrewshire South
6,527 (15.8%) majority - 2024 General ElectionFirst elected: 4th July 2024
Division Voting information
Johanna Baxter voted No - against a party majority and against the House
One of 147 Labour No votes vs 234 Labour Aye votes
Tally: Ayes - 330 Noes - 275
Debates during the 2024 Parliament
Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
Sparring Partners
Lord President of the Council and Leader of the House of Commons
(11 debate interactions)
Department Debates
(10 debate contributions)
(9 debate contributions)
(9 debate contributions)
(6 debate contributions)
Legislation Debates
(504 words contributed)
(308 words contributed)
(47 words contributed)
(39 words contributed)
Paisley and Renfrewshire South Petitions
e-Petitions are administered by Parliament and allow members of the public to express support for a particular issue.
If an e-petition reaches 10,000 signatures the Government will issue a written response.
If an e-petition reaches 100,000 signatures the petition becomes eligible for a Parliamentary debate (usually Monday 4.30pm in Westminster Hall).
of 87,146 signatures (0.42%)
of 160,876 signatures (0.22%)
of 142,334 signatures (0.18%)
of 87,146 signatures (0.42%)
of 160,876 signatures (0.22%)
of 233,304 signatures (0.13%)
of 245,120 signatures (0.11%)
Latest EDMs signed by Johanna Baxter
Commons initiatives
These initiatives were driven by Johanna Baxter, and are more likely to reflect personal policy preferences.
MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.
Johanna Baxter has not been granted any Urgent Questions
Johanna Baxter has not been granted any Adjournment Debates
Johanna Baxter has not introduced any legislation before Parliament
Johanna Baxter has not co-sponsored any Bills in the current parliamentary sitting
Latest 21 Written Questions
(View all written questions)The Economic Crime and Corporate Transparency Act 2023 (ECCTA) will fundamentally reform Companies House, enabling it to play a greater role in tackling economic crime.
The first of these reforms came into force in March 2024 and included new powers to query, challenge and remove inaccurate information, stronger checks on company names, stricter address requirements and greater information sharing powers. These reforms were backed by £63 million of investment and increased fees to fund greater investigation and enforcement capabilities.
Further reforms under the ECCTA, including the introduction of Identity Verification later this year, are in the process of being implemented.
Parliamentary Under Secretary of State (Department for Business and Trade)
1 Department for Science, Innovation & Technology Questions
(View all Johanna Baxter's DSIT questions)In line with our Safer Streets Mission, the Online Safety Act brings much needed protections to the online world by protecting children from harmful and age-inappropriate content, tackling violence against women and girls, and taking down criminal activity. The new laws apply to search services and all companies that allow users to share and post content online or interact with each other, even if the companies providing them are outside the UK.
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
3 Department for Environment, Food and Rural Affairs Questions
(View all Johanna Baxter's Defra questions)The Nature for Climate Fund was established in 2020 as a five-year programme aimed at tackling climate change and boosting biodiversity and it is due to finish in March 2025.
This Government is committed to protecting and restoring nature, trees and peat, which are important to our plans to reduce emissions. We have pledged up to £400 million for tree planting and peatland restoration over the current (2024-25) and next (2025-26) financial year. The detail of how this funding is allocated for 2025-26 is now being finalised through internal business planning, and we will be able to share more once this has concluded.
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
We have pledged up to £400 million in capital spend for tree planting and peatland restoration over the current (2024-25) and next (2025-26) financial year. This includes funding of the Nature for Climate Fund for 2024-25. The detail of how this funding is allocated for 2025-26 is now being finalised through internal business planning, and we will be able to share more once this has concluded.
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
The Government recently announced its support for the Animal Welfare (Import of Dogs, Cats and Ferrets) Bill, a Private Members’ Bill sponsored by Dr Danny Chambers MP. The measures in the Bill will extend to cats and kittens, and close loopholes exploited by unscrupulous pet traders.
Minister of State (Department for Environment, Food and Rural Affairs)
NHS England Specialised Commissioning has recently updated the specialist immunology service specification for adults with deficient immune systems, named the Specialist immunology services for adults with deficient immune systems. This sets out the standards of care that providers of specialist immunology services are expected to meet, including with regards to treatment and monitoring. Further information on the service specification is available at the following link:
The clinical commissioning policy for the use of therapeutic immunoglobulin in England has also recently been updated. The updated document describes all conditions for which therapeutic immunoglobulin is commissioned, including autoimmune conditions, and provides details on the role, dose, and place of therapeutic immunoglobulin in the treatment pathway for individual indications, alongside possible alternative treatment options for use of therapeutic immunoglobulin in both adults and children. Further information on the policy is available at the following link:
Sub Regional Immunoglobulin Assessment Panels (SRIAPs) are in place to provide immunoglobulin stewardship and oversight in line with this policy. In April 2025, a new framework for the supply of immunoglobulin will begin. In March 2025, NHS England Specialised Commissioning provided advice to the SRIAPs regarding patient access to immunoglobulin products, with the introduction of the new framework.
Neither the Department nor NHS England hold data centrally on the exact numbers of those who are clinically defined as immunocompromised. However, a recently published paper in the Journal of Infection identified 477,335 immunocompromised individuals aged 12 years old and over in England. This research paper is available at the following link:
https://www.sciencedirect.com/science/article/pii/S016344532500026X
NHS England Specialised Commissioning is developing a patient information sheet to outline the changes to the range of immunoglobulin products available on the National Health Service. It is intended to support patients who rely on immunoglobulin treatment and may be required to switch to a different immunoglobulin product. This will be shared with patient organisations and clinical teams in April 2025.
The UK Health Security Agency (UKHSA) is committed to working with partners, including NHS England and the Department, to protect the health of immunocompromised patients in the context of infectious disease hazards. Engaging with the Immunocompromised Coalition and other charities supporting vulnerable individuals, in partnership with the Department and the NHS as part of pandemic preparedness, is an important activity for the UKHSA. It enables the prompt implementation of appropriate protective measures with relevant, scalable additional support in the event of a pandemic or another emergency.
The UKHSA has also published COVID-19 guidance, last updated in May 2024, for those individuals whose immune system means they are at higher risk. The guidance is available at the following link:
https://www.gov.uk/government/publications/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk
No assessment has been made of the potential merits of establishing a cross-departmental taskforce for immunocompromised patients.
Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England Specialised Commissioning has recently updated the specialist immunology service specification for adults with deficient immune systems, named the Specialist immunology services for adults with deficient immune systems. This sets out the standards of care that providers of specialist immunology services are expected to meet, including with regards to treatment and monitoring. Further information on the service specification is available at the following link:
The clinical commissioning policy for the use of therapeutic immunoglobulin in England has also recently been updated. The updated document describes all conditions for which therapeutic immunoglobulin is commissioned, including autoimmune conditions, and provides details on the role, dose, and place of therapeutic immunoglobulin in the treatment pathway for individual indications, alongside possible alternative treatment options for use of therapeutic immunoglobulin in both adults and children. Further information on the policy is available at the following link:
Sub Regional Immunoglobulin Assessment Panels (SRIAPs) are in place to provide immunoglobulin stewardship and oversight in line with this policy. In April 2025, a new framework for the supply of immunoglobulin will begin. In March 2025, NHS England Specialised Commissioning provided advice to the SRIAPs regarding patient access to immunoglobulin products, with the introduction of the new framework.
Neither the Department nor NHS England hold data centrally on the exact numbers of those who are clinically defined as immunocompromised. However, a recently published paper in the Journal of Infection identified 477,335 immunocompromised individuals aged 12 years old and over in England. This research paper is available at the following link:
https://www.sciencedirect.com/science/article/pii/S016344532500026X
NHS England Specialised Commissioning is developing a patient information sheet to outline the changes to the range of immunoglobulin products available on the National Health Service. It is intended to support patients who rely on immunoglobulin treatment and may be required to switch to a different immunoglobulin product. This will be shared with patient organisations and clinical teams in April 2025.
The UK Health Security Agency (UKHSA) is committed to working with partners, including NHS England and the Department, to protect the health of immunocompromised patients in the context of infectious disease hazards. Engaging with the Immunocompromised Coalition and other charities supporting vulnerable individuals, in partnership with the Department and the NHS as part of pandemic preparedness, is an important activity for the UKHSA. It enables the prompt implementation of appropriate protective measures with relevant, scalable additional support in the event of a pandemic or another emergency.
The UKHSA has also published COVID-19 guidance, last updated in May 2024, for those individuals whose immune system means they are at higher risk. The guidance is available at the following link:
https://www.gov.uk/government/publications/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk
No assessment has been made of the potential merits of establishing a cross-departmental taskforce for immunocompromised patients.
Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England Specialised Commissioning has recently updated the specialist immunology service specification for adults with deficient immune systems, named the Specialist immunology services for adults with deficient immune systems. This sets out the standards of care that providers of specialist immunology services are expected to meet, including with regards to treatment and monitoring. Further information on the service specification is available at the following link:
The clinical commissioning policy for the use of therapeutic immunoglobulin in England has also recently been updated. The updated document describes all conditions for which therapeutic immunoglobulin is commissioned, including autoimmune conditions, and provides details on the role, dose, and place of therapeutic immunoglobulin in the treatment pathway for individual indications, alongside possible alternative treatment options for use of therapeutic immunoglobulin in both adults and children. Further information on the policy is available at the following link:
Sub Regional Immunoglobulin Assessment Panels (SRIAPs) are in place to provide immunoglobulin stewardship and oversight in line with this policy. In April 2025, a new framework for the supply of immunoglobulin will begin. In March 2025, NHS England Specialised Commissioning provided advice to the SRIAPs regarding patient access to immunoglobulin products, with the introduction of the new framework.
Neither the Department nor NHS England hold data centrally on the exact numbers of those who are clinically defined as immunocompromised. However, a recently published paper in the Journal of Infection identified 477,335 immunocompromised individuals aged 12 years old and over in England. This research paper is available at the following link:
https://www.sciencedirect.com/science/article/pii/S016344532500026X
NHS England Specialised Commissioning is developing a patient information sheet to outline the changes to the range of immunoglobulin products available on the National Health Service. It is intended to support patients who rely on immunoglobulin treatment and may be required to switch to a different immunoglobulin product. This will be shared with patient organisations and clinical teams in April 2025.
The UK Health Security Agency (UKHSA) is committed to working with partners, including NHS England and the Department, to protect the health of immunocompromised patients in the context of infectious disease hazards. Engaging with the Immunocompromised Coalition and other charities supporting vulnerable individuals, in partnership with the Department and the NHS as part of pandemic preparedness, is an important activity for the UKHSA. It enables the prompt implementation of appropriate protective measures with relevant, scalable additional support in the event of a pandemic or another emergency.
The UKHSA has also published COVID-19 guidance, last updated in May 2024, for those individuals whose immune system means they are at higher risk. The guidance is available at the following link:
https://www.gov.uk/government/publications/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk
No assessment has been made of the potential merits of establishing a cross-departmental taskforce for immunocompromised patients.
Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England Specialised Commissioning has recently updated the specialist immunology service specification for adults with deficient immune systems, named the Specialist immunology services for adults with deficient immune systems. This sets out the standards of care that providers of specialist immunology services are expected to meet, including with regards to treatment and monitoring. Further information on the service specification is available at the following link:
The clinical commissioning policy for the use of therapeutic immunoglobulin in England has also recently been updated. The updated document describes all conditions for which therapeutic immunoglobulin is commissioned, including autoimmune conditions, and provides details on the role, dose, and place of therapeutic immunoglobulin in the treatment pathway for individual indications, alongside possible alternative treatment options for use of therapeutic immunoglobulin in both adults and children. Further information on the policy is available at the following link:
Sub Regional Immunoglobulin Assessment Panels (SRIAPs) are in place to provide immunoglobulin stewardship and oversight in line with this policy. In April 2025, a new framework for the supply of immunoglobulin will begin. In March 2025, NHS England Specialised Commissioning provided advice to the SRIAPs regarding patient access to immunoglobulin products, with the introduction of the new framework.
Neither the Department nor NHS England hold data centrally on the exact numbers of those who are clinically defined as immunocompromised. However, a recently published paper in the Journal of Infection identified 477,335 immunocompromised individuals aged 12 years old and over in England. This research paper is available at the following link:
https://www.sciencedirect.com/science/article/pii/S016344532500026X
NHS England Specialised Commissioning is developing a patient information sheet to outline the changes to the range of immunoglobulin products available on the National Health Service. It is intended to support patients who rely on immunoglobulin treatment and may be required to switch to a different immunoglobulin product. This will be shared with patient organisations and clinical teams in April 2025.
The UK Health Security Agency (UKHSA) is committed to working with partners, including NHS England and the Department, to protect the health of immunocompromised patients in the context of infectious disease hazards. Engaging with the Immunocompromised Coalition and other charities supporting vulnerable individuals, in partnership with the Department and the NHS as part of pandemic preparedness, is an important activity for the UKHSA. It enables the prompt implementation of appropriate protective measures with relevant, scalable additional support in the event of a pandemic or another emergency.
The UKHSA has also published COVID-19 guidance, last updated in May 2024, for those individuals whose immune system means they are at higher risk. The guidance is available at the following link:
https://www.gov.uk/government/publications/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk
No assessment has been made of the potential merits of establishing a cross-departmental taskforce for immunocompromised patients.
Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England Specialised Commissioning has recently updated the specialist immunology service specification for adults with deficient immune systems, named the Specialist immunology services for adults with deficient immune systems. This sets out the standards of care that providers of specialist immunology services are expected to meet, including with regards to treatment and monitoring. Further information on the service specification is available at the following link:
The clinical commissioning policy for the use of therapeutic immunoglobulin in England has also recently been updated. The updated document describes all conditions for which therapeutic immunoglobulin is commissioned, including autoimmune conditions, and provides details on the role, dose, and place of therapeutic immunoglobulin in the treatment pathway for individual indications, alongside possible alternative treatment options for use of therapeutic immunoglobulin in both adults and children. Further information on the policy is available at the following link:
Sub Regional Immunoglobulin Assessment Panels (SRIAPs) are in place to provide immunoglobulin stewardship and oversight in line with this policy. In April 2025, a new framework for the supply of immunoglobulin will begin. In March 2025, NHS England Specialised Commissioning provided advice to the SRIAPs regarding patient access to immunoglobulin products, with the introduction of the new framework.
Neither the Department nor NHS England hold data centrally on the exact numbers of those who are clinically defined as immunocompromised. However, a recently published paper in the Journal of Infection identified 477,335 immunocompromised individuals aged 12 years old and over in England. This research paper is available at the following link:
https://www.sciencedirect.com/science/article/pii/S016344532500026X
NHS England Specialised Commissioning is developing a patient information sheet to outline the changes to the range of immunoglobulin products available on the National Health Service. It is intended to support patients who rely on immunoglobulin treatment and may be required to switch to a different immunoglobulin product. This will be shared with patient organisations and clinical teams in April 2025.
The UK Health Security Agency (UKHSA) is committed to working with partners, including NHS England and the Department, to protect the health of immunocompromised patients in the context of infectious disease hazards. Engaging with the Immunocompromised Coalition and other charities supporting vulnerable individuals, in partnership with the Department and the NHS as part of pandemic preparedness, is an important activity for the UKHSA. It enables the prompt implementation of appropriate protective measures with relevant, scalable additional support in the event of a pandemic or another emergency.
The UKHSA has also published COVID-19 guidance, last updated in May 2024, for those individuals whose immune system means they are at higher risk. The guidance is available at the following link:
https://www.gov.uk/government/publications/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk
No assessment has been made of the potential merits of establishing a cross-departmental taskforce for immunocompromised patients.
Parliamentary Under-Secretary (Department of Health and Social Care)
The Home Office works across Government to tackle the Serious Organised Crime threat linked to Russia including Russia-linked illicit finance in the UK.
This was recently demonstrated through the NCA’s Operation DESTABILISE which exposed and disrupted Russian money laundering networks supporting serious and organised crime.
In addition to our domestic efforts, we work with like-minded international partners to build capacity in key law enforcement institutions and the judiciary to help tackle, and enhance resilience against, Russia-linked organised crime groups.
Minister of State (Home Office)
The Taskforce has reflected on last year’s elections and is now taking forward a programme of work to ensure lessons are learned.
This includes work to tackle the unacceptable instances of harassment and intimidation of our elected representatives that we saw during the General Election.
This vital work is ongoing, and I will update the House in due course.
Minister of State (Home Office)
Integrating uncrewed systems with our crewed platforms is a critical part of ensuring the Royal Navy can effectively respond to competition, crisis and conflict in the future. Delivering uncrewed systems will feature heavily in the design specifications of the Multi-Role Support Ships – the next generation of amphibious ships to support the Commando forces. The Ministry of Defence is collaborating with industry to assess the merits of uncrewed systems with trials and spiral development, while learning operational lessons from Ukraine.
Minister of State (Ministry of Defence)
We are working with Ukraine and international partners to secure commercial shipping and shipping routes in the Black Sea, including Ukraine's maritime corridor. The 100 Year Partnership will help with this endeavour through the provision of training and equipment to Ukraine, to prevent and deter Russian attacks.
The 100 Partnership Declaration has made clear that freedom of navigation for commercial shipping in the Black Sea and beyond must be upheld and the UK will continue to do all it can to help Ukraine through the strengthening of its maritime forces.
The UK co-leads the maritime capability coalition with Norway and this work supports Ukraine’s maritime capabilities now and in the future.
Parliamentary Under-Secretary (Ministry of Defence)
NATO made a long-term commitment to Ukraine and has been clear that Ukraine’s rightful place is in NATO. The Prime Minister has reaffirmed the UK’s commitment to Ukraine’s irreversible path to NATO membership, as agreed by all Allies at the Washington Summit.
That is a process that will take time, and for now our priority is to make sure Ukraine is in the strongest possible position on the battlefield and in any potential negotiations to come.
Parliamentary Under-Secretary (Ministry of Defence)
The programme achieved a significant milestone with the successful first SPEAR guided firing conducted at the end of 2024, demonstrating progress despite the challenges outlined in the Infrastructure and Project Authority's Annual Report 2023-24, which remain ongoing. Since the report, the programme has faced additional challenges stemming from interdependencies with international partners, requiring significant adjustments to maintain progress. The SRO, in collaboration with Defence Equipment and Support and Industry, is prioritising the development of a revised and viable baseline, which is planned to be finalised in Quarter two of financial year 2025-26.
Minister of State (Ministry of Defence)
The Wedgetail programme has seen the first aircraft complete three test flights, be painted in the markings of 8 Squadron and continues with the installation of mission equipment at STS Aviation at Birmingham Airport, before entering the test and evaluation phase later this year. Aircraft two and three are progressing with integrating their modifications as planned.
The infrastructure programme at RAF Lossiemouth has delivered the combined Poseidon and Wedgetail engineering line facility, as well as 8 Squadron headquarters office accommodation, with the final elements of the technical facility expected to be handed over in March 2025.
Minister of State (Ministry of Defence)
Protector training has now transferred to the UK having completed four aircrew basic qualification courses in the United States. Further, four Protector Air Vehicles have now been delivered to RAF Waddington, where they are being maintained by 31 Squadron engineers. The required Test and Evaluation activity and UK training is underway, ahead of the planned platform in-service declaration later in 2025.
From a broader perspective, the UK is leading the MQ-9 International Cooperation Support Partnership which now has seven participant members (UK, Belgium, Canada, Denmark, Germany, Italy, Spain) and five observer nations (Greece, Lithuania, Norway, Qatar, Sweden), with an expectation of further growth. The UK is working closely with the NATO Intelligence, Surveillance and Reconnaissance Force to scope options to provide Protector in support of operations in the Northern Atlantic and Arctic regions. Opportunities for NATO investment in RAF Waddington to support growth are also progressing.
Minister of State (Ministry of Defence)
The consultation to introduce Employment Tribunal fees was published under the last Government and no decisions have yet been made on the proposal.
Secretary of State for Transport